Interim Results for the six months to 30 June 2026

AI SummaryClose X

Poolbeg Pharma plc reported its interim results for the six months ending June 30, 2026, highlighting strong operational progress with its TOPICAL trial for POLB 001, which has dosed eight participants and received positive interim safety cohort review. The company maintained a robust financial position with £4.8 million in cash, further bolstered by a £3.5 million fundraise in July 2026, extending the cash runway into Q2 2028 and funding both the POLB 001 TOPICAL trial and an oral GLP-1 proof-of-concept trial to completion. Key developments include a positive FDA pre-IND meeting, preclinical data supporting POLB 001's potential in preventing Cytokine Release Syndrome and enhancing azacitidine efficacy, and independent US payer research indicating multi-billion-dollar peak sales potential for POLB 001. The company also strengthened its intellectual property portfolio with patent grants in Canada, Australia, and Europe for its cancer immunotherapy-induced CRS patent family. The reported loss for the period was £1.9 million, an improvement from £2.2 million in the prior year's comparable period.

Disclaimer*

UK 100

Latest directors dealings